Does the media refer more to WVE or DNLI?

In the previous week, WAVE Life Sciences had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for WAVE Life Sciences and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat WAVE Life Sciences' score of 1.02 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, WVE or GRAL?

WAVE Life Sciences has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio WAVE Life Sciences $42.73M 21.17 -$204.38M -$1.09 N/A GRAIL $165.26M 20.60 -$408.35M -$9.75 N/A

Is WVE or GRAL more profitable?

GRAIL has a net margin of -236.95% compared to WAVE Life Sciences' net margin of -309.73%. GRAIL's return on equity of -15.88% beat WAVE Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets WAVE Life Sciences -309.73% -50.36% -40.06% GRAIL -236.95% -15.88% -14.02%

Does the media favor WVE or GRAL?

In the previous week, GRAIL had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 9 mentions for GRAIL and 4 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.02 beat GRAIL's score of 0.96 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, WVE or VCYT?

Veracyte has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio WAVE Life Sciences $42.73M 21.17 -$204.38M -$1.09 N/A Veracyte $517.15M 6.35 $66.35M $1.41 28.99

Does the media favor WVE or VCYT?

In the previous week, Veracyte had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 6 mentions for Veracyte and 4 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.02 beat Veracyte's score of 0.44 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to WVE or ABCL?

In the previous week, WAVE Life Sciences had 2 more articles in the media than AbCellera Biologics. MarketBeat recorded 4 mentions for WAVE Life Sciences and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.02 beat WAVE Life Sciences' score of 1.02 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IDYA or WVE?

In the previous week, IDEAYA Biosciences had 9 more articles in the media than WAVE Life Sciences. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 4 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.02 beat IDEAYA Biosciences' score of 0.64 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

WAVE Life Sciences (WVE) Competitors

$4.59 -0.08 (-1.71%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.66 +0.07 (+1.53%)

As of 09/11/2026 07:59 PM Eastern

Compare

WVE vs. DNLI, GRAL, VCYT, ABCL, and IDYA

Should you buy WAVE Life Sciences stock or one of its competitors? WAVE Life Sciences's main competitors and comparable companies include Denali Therapeutics (DNLI), GRAIL (GRAL), Veracyte (VCYT), AbCellera Biologics (ABCL), and IDEAYA Biosciences (IDYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does WAVE Life Sciences compare to Denali Therapeutics?

WAVE Life Sciences (NASDAQ:WVE) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

WAVE Life Sciences has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	21.17	-$204.38M	-$1.09	N/A
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A

WAVE Life Sciences has a beta of -1.3, meaning that its share price is 230% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

WAVE Life Sciences presently has a consensus price target of $22.31, indicating a potential upside of 386.11%. Denali Therapeutics has a consensus price target of $35.85, indicating a potential upside of 69.97%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe WAVE Life Sciences is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Denali Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Denali Therapeutics	N/A	-55.27%	-44.24%

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, WAVE Life Sciences had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for WAVE Life Sciences and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat WAVE Life Sciences' score of 1.02 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

WAVE Life Sciences beats Denali Therapeutics on 11 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to GRAIL?

WAVE Life Sciences (NASDAQ:WVE) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

WAVE Life Sciences has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	21.17	-$204.38M	-$1.09	N/A
GRAIL	$165.26M	20.60	-$408.35M	-$9.75	N/A

GRAIL has a net margin of -236.95% compared to WAVE Life Sciences' net margin of -309.73%. GRAIL's return on equity of -15.88% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
GRAIL	-236.95%	-15.88%	-14.02%

89.7% of WAVE Life Sciences shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 1.8% of GRAIL shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

WAVE Life Sciences has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.25, indicating that its stock price is 225% more volatile than the broader market.

In the previous week, GRAIL had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 9 mentions for GRAIL and 4 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.02 beat GRAIL's score of 0.96 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

WAVE Life Sciences presently has a consensus target price of $22.31, suggesting a potential upside of 386.11%. GRAIL has a consensus target price of $71.11, suggesting a potential downside of 6.72%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe WAVE Life Sciences is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45

Summary

WAVE Life Sciences beats GRAIL on 10 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to Veracyte?

WAVE Life Sciences (NASDAQ:WVE) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Veracyte had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 6 mentions for Veracyte and 4 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.02 beat Veracyte's score of 0.44 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	21.17	-$204.38M	-$1.09	N/A
Veracyte	$517.15M	6.35	$66.35M	$1.41	28.99

89.7% of WAVE Life Sciences shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 1.6% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

WAVE Life Sciences has a beta of -1.3, indicating that its share price is 230% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

WAVE Life Sciences currently has a consensus price target of $22.31, suggesting a potential upside of 386.11%. Veracyte has a consensus price target of $55.78, suggesting a potential upside of 36.48%. Given WAVE Life Sciences' higher probable upside, equities research analysts plainly believe WAVE Life Sciences is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Veracyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.91

Veracyte has a net margin of 20.37% compared to WAVE Life Sciences' net margin of -309.73%. Veracyte's return on equity of 9.26% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Veracyte	20.37%	9.26%	8.61%

Summary

Veracyte beats WAVE Life Sciences on 11 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to AbCellera Biologics?

WAVE Life Sciences (NASDAQ:WVE) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AbCellera Biologics has a net margin of -248.83% compared to WAVE Life Sciences' net margin of -309.73%. AbCellera Biologics' return on equity of -17.49% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

WAVE Life Sciences has a beta of -1.3, indicating that its share price is 230% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

In the previous week, WAVE Life Sciences had 2 more articles in the media than AbCellera Biologics. MarketBeat recorded 4 mentions for WAVE Life Sciences and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.02 beat WAVE Life Sciences' score of 1.02 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics has higher revenue and earnings than WAVE Life Sciences. AbCellera Biologics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	21.17	-$204.38M	-$1.09	N/A
AbCellera Biologics	$66.17M	50.46	-$146.41M	-$0.54	N/A

WAVE Life Sciences presently has a consensus target price of $22.31, suggesting a potential upside of 386.11%. AbCellera Biologics has a consensus target price of $12.83, suggesting a potential upside of 17.85%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe WAVE Life Sciences is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

AbCellera Biologics beats WAVE Life Sciences on 11 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

IDEAYA Biosciences presently has a consensus target price of $52.69, suggesting a potential upside of 40.18%. WAVE Life Sciences has a consensus target price of $22.31, suggesting a potential upside of 386.11%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

IDEAYA Biosciences has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.3, meaning that its stock price is 230% less volatile than the broader market.

IDEAYA Biosciences has higher revenue and earnings than WAVE Life Sciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	15.10	-$113.70M	-$1.94	N/A
WAVE Life Sciences	$42.73M	21.17	-$204.38M	-$1.09	N/A

IDEAYA Biosciences has a net margin of -75.93% compared to WAVE Life Sciences' net margin of -309.73%. IDEAYA Biosciences' return on equity of -16.73% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

In the previous week, IDEAYA Biosciences had 9 more articles in the media than WAVE Life Sciences. MarketBeat recorded 13 mentions for IDEAYA Biosciences and 4 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.02 beat IDEAYA Biosciences' score of 0.64 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

IDEAYA Biosciences and WAVE Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

Get WAVE Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WVE vs. The Competition

Export

Metric	WAVE Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$920.22M	$3.85B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-4.21	14.18	274.10	25.29
Price / Sales	21.17	1,477.55	655.45	98.96
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	1.48	15.12	10.33	6.20
Net Income	-$204.38M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-5.56%	-4.35%	-3.33%	-2.35%
1 Month Performance	-12.40%	-0.03%	-0.41%	-2.77%
1 Year Performance	-34.15%	40.63%	19.22%	7.63%

WAVE Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WVE WAVE Life Sciences	2.9719 of 5 stars	$4.59 -1.7%	$22.31 +386.1%	-35.9%	$920.22M	$42.73M	N/A	240	News Coverage Positive News
DNLI Denali Therapeutics	3.7576 of 5 stars	$22.28 -2.3%	$35.85 +60.9%	+42.3%	$3.64B	$330.53M	N/A	430	Positive News
GRAL GRAIL	0.6883 of 5 stars	$80.34 -0.3%	$67.78 -15.6%	+97.2%	$3.60B	$147.17M	N/A	1,360	Analyst Upgrade
VCYT Veracyte	4.3707 of 5 stars	$42.53 -4.8%	$54.33 +27.8%	+28.3%	$3.59B	$517.15M	30.16	790	Analyst Upgrade
ABCL AbCellera Biologics	2.6027 of 5 stars	$11.43 -1.2%	$12.83 +12.3%	+136.2%	$3.55B	$75.13M	N/A	500	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WVE) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

WAVE Life Sciences (WVE) Competitors

WVE vs. DNLI, GRAL, VCYT, ABCL, and IDYA

How does WAVE Life Sciences compare to Denali Therapeutics?

Summary

How does WAVE Life Sciences compare to GRAIL?

Summary

How does WAVE Life Sciences compare to Veracyte?

Summary

How does WAVE Life Sciences compare to AbCellera Biologics?

Summary

How does WAVE Life Sciences compare to IDEAYA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

WAVE Life Sciences (WVE) Competitors

WVE vs. DNLI, GRAL, VCYT, ABCL, and IDYA

How does WAVE Life Sciences compare to Denali Therapeutics?

Which has preferable earnings and valuation, WVE or DNLI?

Which has more risk & volatility, WVE or DNLI?

Do analysts prefer WVE or DNLI?

Is WVE or DNLI more profitable?

Do institutionals & insiders believe in WVE or DNLI?

Does the media refer more to WVE or DNLI?

Summary

How does WAVE Life Sciences compare to GRAIL?

Which has preferable valuation & earnings, WVE or GRAL?

Is WVE or GRAL more profitable?

Do institutionals and insiders hold more shares of WVE or GRAL?

Which has more volatility and risk, WVE or GRAL?

Does the media favor WVE or GRAL?

Do analysts recommend WVE or GRAL?

Summary

How does WAVE Life Sciences compare to Veracyte?

Does the media favor WVE or VCYT?

Which has stronger earnings and valuation, WVE or VCYT?

Do insiders and institutionals hold more shares of WVE or VCYT?

Which has more volatility & risk, WVE or VCYT?

Do analysts recommend WVE or VCYT?

Is WVE or VCYT more profitable?

Summary

How does WAVE Life Sciences compare to AbCellera Biologics?

Do insiders & institutionals hold more shares of WVE or ABCL?

Is WVE or ABCL more profitable?

Which has more risk and volatility, WVE or ABCL?

Does the media refer more to WVE or ABCL?

Which has better earnings & valuation, WVE or ABCL?

Do analysts recommend WVE or ABCL?

Summary

How does WAVE Life Sciences compare to IDEAYA Biosciences?

Do analysts rate IDYA or WVE?

Which has more risk and volatility, IDYA or WVE?

Which has better earnings and valuation, IDYA or WVE?

Is IDYA or WVE more profitable?

Does the media refer more to IDYA or WVE?

Do insiders and institutionals hold more shares of IDYA or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools